CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis

Tissue Antigens

Volumn 51, Issue 1, 1998, Pages 62-66

  Seidl, C ^a,c   Donner, H ^b   Fischer, B ^a   Usadel, K H ^b   Seifried, E ^a   Kaltwasser, J P ^b   Badenhoop, K ^b  

^a Institute of Transfusion Medicine and Immunohaematology   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Inst F Transfusionsmedizin I   (Germany)

Author keywords

CTLA4; HLA; Polymorphism; Rheumatoid arthritis

Indexed keywords

ALANINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; THREONINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHROMOSOME 6; CODON; CONTROLLED STUDY; DISEASE PREDISPOSITION; EXON; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HLA SYSTEM; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0031963283     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb02947.x     Document Type: Article

References (40)

1. Snowden N, Kay RA. Immunology of systemic rheumatoid disease. In: Saklatvala J, Walport MJ, ed. Immunology of rheumatoid disease. Br Med Bull 1995: 51: 437-448.
2. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994: 56: 389-466.
3. Hiraiwa A, Yamanaka K, Kwok WW et al. Structural requirements for recognition of the HLA-Dw14 class II epitope: a key HLA determinant associated with rheumatoid arthritis. Proc Natl Acad Sci U S A 1990: 87: 8051-8055.
4. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understand the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987: 30: 1205-1213.
5. Gough A, Faint J, Salmon M et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994: 37: 1166-1170.
6. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992: 117: 801-806.
7. Toda Y, Minamikawa Y, Akagi S et al. Rheumatoid-susceptible alleles of HLA-DRB1 are genetically recessive to non-susceptible alleles in the progression of bone destruction in the wrists and fingers of patients with RA. Ann Rheum Dis 1994: 53: 587-592.
8. McMahon MJ, Hillarby MC, Clarkson RW, Hollis S, Grennan DM. Major histocompatibility complex variants and articular disease severity in rheumatoid arthritis. Br J Rheumatol 1993: 32: 899-902.
9. Albani S, Carson DA, Roudier J. Genetic and environmental factors in the immune pathogenesis of rheumatoid arthritis. Rheum Dis Clin North Am 1992: 18: 729-740.
10. Weyand CM, Goronzy JJ. Inherited and noninherited risk factors in rheumatoid arthritis. Curr Opin Rheumatol 1995: 7: 206-213.
11. Dariavach P, Mattei MG, Golstein P, Lefranc MP. Human Ig superfamily CTLA4 gene: chromosomal localisation and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988: 18: 1901-1905.
12. Noel PJ, Boise LH, Thompson CB. Regulation of T cell activation by CD28 and CTLA4. Adv Exp Med Biol 1996: 406: 209-217.
13. Tivol EA, Schweitzer AN, Sharpe AH. Costimulation and autoimmunity. Curr Opin Immunol 1996: 8: 822-830.
14. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995: 80: 41-45.
15. Polymeropoulos MH, Xiao H, Rath DS, Merril CR. Dinucleotide repeat polymorphism at the human CTLA4 gene. Nucleic Acids Res 1991: 19: 4018.
16. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure and chromosomal location. J Immunol 1991: 147: 1037-1044.
17. Nistito L, Buzetti R, Pritchard LE et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Hum Mol Genet 1996: 5: 1075-1080.
18. Donner H, Rau H, Walfish PG et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus (IDDM). J Clin Endocrinol Metab (in press).
19. Bein G, Gläser R, Kirchner H. Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens 1992: 39: 68-73.
20. Tiwari JL, Terasaki PI. HLA and disease association. New York: Springer-Verlag, 1985: 18-27.
21. Hune CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994: 15: 321-331.
22. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996: 4: 535-543.
23. Gribben JG, Freeman GJ, Boussiotis VA et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A 1995: 92: 811-815.
24. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995: 3: 541-547.
25. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995: 270: 985-988.
26. Marengere LEM, Waterhouse P, Duncan GS, Mittrücker H-W, Feng G-S, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996: 272: 1170-1173.
27. Thomas R, Quinn C. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J Immunol 1996: 15: 3074-3086.
28. Knorerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995: 96: 987-993.
29. Webb LMC, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockage of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996: 26: 2320-2328.
30. Garcia-Cozar FJ, Molina IJ, Cuadrado MJ, Marubayashi M, Pena J, Santamaria M. Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematodes (SLE) patients. Clin Exp Immunol 1996: 104: 72-79.
31. + cell subsets shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. J Immunol 1996: 156: 1262-1268.
32. Jenkins RN, Nikaein A, Zimmermann A, Meek K, Lipsky PE. T cell receptor V beta gene bias in rheumatoid arthritis. J Clin Invest 1993: 92: 2688-2701.
33. Seyfried CE, Mickelson E, Hansen JA, Nepom GT. A specific nucleotide sequence defines a functional T-cell recognition epitope shared by diverse HLA-DR specificities. Hum Immunol 1988: 21: 289-299.
34. Weyand CM, Oppitz U, Hicok K, Goronzy JJ, Selection of T cell receptor V-beta elements by HLA-DR determinants predisposing to rheumatoid arthritis. Arthritis Rheum 1992: 35: 990-998.
35. Lunardi C, Marguerite C, So AK. An altered repertoire of T cell receptor V gene expression by rheumatoid synovial fluid T lymphocytes. Clin Exp Immunol 1992: 90: 440-446.
36. Weyand CM, Goronzy JJ. Disease mechanisms in rheumatoid arthritis: gene dosage effect of HLA-DR haplotypes. J Lab Clin Med 1994: 124: 335-338.
37. + T-lymphocytes on the basis of CDR3 diversity. Int Immunol 1994: 6: 897-907.
38. Goronzy JJ and Weyand CM. Interplay of T lymphocytes and HLA-DR molecules in rheumatoid arthritis. Curr Opin Rheumatol 1993: 5: 169-177.
39. + cells in rheumatoid arthritis synovial fluid. Arthritis Rheum 1992: 35: 865-873.
40. +) T cells in patients with rheumatoid arthritis. Arthritis Rheum 1997: 40: 237-248.